Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
Amsterdam Neuroscience · Amsterdam UMC Location Vrije Universiteit Amsterdam · +40 more institutions
Abstract
Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date.
To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions. DATA SOURCES: PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC. STUDY SELECTION: Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex. DATA EXTRACTION AND SYNTHESIS: Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept. MAIN OUTCOME AND MEASURE: The cNfL levels adjusted for age and sex across diagnoses.
Citation impact
- FWCI
- 32.90
- Percentile
- 100%
- References
- 107
Authors
78- CBClaire BridelCorresponding
Amsterdam Neuroscience
- WNWessel N. van Wieringen
Amsterdam UMC Location Vrije Universiteit Amsterdam
- HZHenrik Zetterberg
Sahlgrenska University Hospital, UK Dementia Research Institute, National Hospital for Neurology and Neurosurgery, University College London, University of Gothenburg
- BMBetty M. Tijms
Amsterdam Neuroscience
- CECharlotte E. Teunissen
Amsterdam Neuroscience
Topics & keywords
- Cerebrospinal fluid
- Medicine
- Cohort
- Neurology
- Lumbar puncture
- Biomarker
- Cohort study
- Medical diagnosis
Funding
- ELEli Lilly and Company
- AAstraZeneca
- BBayer
- SSanofi
- BBiogen
- CFCHDI Foundation
- TPTeva Pharmaceutical Industries
- IYItä-Suomen Yliopisto
- UBUniversität Basel
- ECEuropean Committee for Treatment and Research in Multiple Sclerosis
- EJEU Joint Programme – Neurodegenerative Disease Research
- EFEuropean Federation of Pharmaceutical Industries and AssociationsAward: 115372
- EHEuropean Huntington's Disease Network
- MNMotor Neurone Disease AssociationAward: MR/K01014X/1
- ECEuropean CommissionAwards: 733050202, 115372, 633666
- BHBayer HealthCare
- NRNational Research Foundation
- ZZonMwAwards: 733050202, 733050822, 733050824
- RURadboud Universiteit
- VUVrije Universiteit Amsterdam
- UMUniversiteit Maastricht
- GHGentofte Hospital
- NONederlandse Organisatie voor Wetenschappelijk OnderzoekAward: 733050822
- KIKarolinska Institutet
- KYKuopion Yliopistollinen Sairaala
- CMChina Medical University Hospital
- SUSahlgrenska Universitetssjukhuset
- UDUniversità degli Studi di Ferrara
- CMChina Medical University
- RERed Española de Esclerosis Múltiple
- KGKarl-Franzens-Universität Graz
- MUMedizinische Universität Graz
- SDStichting Dioraphte
- ANAlzheimer Nederland
- HLH. Lundbeck A/S
- BHBarts Health NHS Trust
- JPJanssen Prevention Center
- AAllergan
- UOUniversity of California, San Diego
- ARAvid Radiopharmaceuticals
- MRMedical Research CouncilAwards: MR/K01014X/1, MR/M008592/1
- EAEconomic and Social Research CouncilAward: ES/K000365/1
- IDInstituto de Salud Carlos III